שווי פעילות לרווח לפני ריבית, מסים ופחת Scinai Immunotherapeutics Ltd. (SCNI)

The market valuation chart for Scinai Immunotherapeutics (SCNI), whose operations are based on creating targeted immunotherapy via the NanoAb platform and patent protection for B2B projects, demonstrates the 0.00 metric. Future growth relies on the success of nano-antibodies against autoimmune pathologies and viral infections, as well as the volume of grants. Meanwhile, business stability is constrained by debt and a reliance on third-party manufacturing sites during the development of dermatitis therapy.

The development of the nanoantibody platform by Scinai Immunotherapeutics (SCNI) to combat pandemics is reflected in the enterprise value-to-EBITDA ratio. This indicator aggregates market capitalization with debt and taxes, comparing the total cost of acquiring the business against its operating profit. A decrease in the ratio signals that assets are undervalued, whereas a sharp increase indicates an overpayment for the company's innovative potential.